论文部分内容阅读
目的探讨喘可治注射液联合孟鲁司特预防婴幼儿反复喘息的临床疗效。方法将72例反复喘息患儿随机分为治疗组38例和对照组34例。对照组予以常规综合治疗,喘息症状缓解出院后,无任何干预治疗。治疗组在常规综合治疗基础上应用喘可治注射液和孟鲁司特,疗程12周。观察治疗结束时肺功能变化及停药后1年内呼吸道感染发生率与喘息性疾病发生率。结果治疗3个月后治疗组的肺功能指标达峰时间比(TPEF/TE)(30.75±6.29vs27.25±7.06,P<0.05)、达峰容积比(VPEF/VE)(32.52±4.83vs29.55±5.11,P<0.05)均高于对照组;1年内治疗组呼吸道感染发生率(26.32%vs64.71%,P<0.01)与喘息性疾病发生率(18.42%vs44.12%,P<0.01)均低于对照组。结论喘可治注射液联合孟鲁司特治疗婴幼儿反复喘息疗效确切,依从性好。
Objective To investigate the clinical efficacy of chuankezhi injection combined with montelukast in the prevention of recurrent wheezing in infants. Methods 72 cases of recurrent wheezing were randomly divided into treatment group 38 cases and control group 34 cases. The control group was given conventional comprehensive treatment, wheezing relieved after discharge, without any intervention. Treatment group in the conventional comprehensive treatment based on the application of chuankezhi injection and montelukast, treatment for 12 weeks. Observe the change of lung function at the end of treatment and the incidence of respiratory tract infection and the incidence of wheezing disease within 1 year after discontinuation. Results After 3 months of treatment, the peak time of pulmonary function index (TPEF / TE) (30.75 ± 6.29 vs 27.25 ± 7.06, P <0.05) and peak volume ratio (VPEF / VE) of 32.52 ± 4.83vs29 .55 ± 5.11, P <0.05) were higher than those in the control group. The incidence of respiratory tract infection (26.32% vs64.71%, P <0.01) and the incidence of wheezing disease in the treatment group within one year (18.42% vs44.12%, P <0.01) were lower than the control group. Conclusion Chuankezhi injection combined with montelukast treatment of recurrent wheeze in infants and young children is effective and has good compliance.